Nuclear area is a prognostic determinant in advanced colorectal cancer

Anticancer Research

Volumn 25, Issue 4, 2005, Pages 3083-3088

  Buhmeida, Abdelbaset ^a,b   Ristamäki, Raija ^a   Lamlum, Hanan ^a,b   Bendardaf, Riyad ^a,b   Heikkilä, Suvi ^a   Collan, Yrjö ^a   Syrjänen, Kari ^a   Pyrhönen, Seppo ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Adjuvant therapy; Colorectal cancer; Nuclear area; Nuclear morphometry; Prognosis

Indexed keywords

IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL NUCLEUS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 22944433166     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Gatta G, Faivre J, Capocaccia R and Ponz de Leon M: Survival of colorectal cancer patients in Europe during the period 1978-1989. Eur J Cancer 34(14): 2176-2183, 1998.
2. Repetto L, Venturino A, Fratino L, Serraino D, Troisi G, Gianni W and Pietropaolo M: Geriatric oncology: a clinical approach to the older patient with cancer. Eur J Cancer 39(7): 870-880, 2003.
3. Wymenga AN, Slaets JP and Sleijfer DT: Treatment of cancer in old age, shortcomings and challenges. Neth J Med 59(5): 259-266, 2001.
4. Franceschi S and La Vecchia C: Cancer epidemiology in the elderly. Crit Rev Oncol Hematol 39(3): 219-226, 2001.
5. Donohue JH, Williams S, Cha S, Windschitl HE, Witzig TE, Nelson H, Fitzgibbons RJ Jr, Wieand HS and Moertel CG: Perioperative blood transfusions do not affect disease recurrence of patients undergoing curative resection of colorectal carcinoma: a Mayo/North Central Cancer Treatment Group study. J Clin Oncol 13(7): 1671-1678, 1995.
6. Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer statistics. CA Cancer J Clin 57(2): 144, 2001.
7. Steele G Jr, Ravikumar TS and Benotti PN: Surgical treatments for recurrent colorectal cancer. Cancer 65(5): 723-730, 1990.
8. Bruckner HW and Motwani BT: Chemotherapy of advanced cancer of the colon and rectum. Semin Oncol 18(5): 443-461, 1991.
9. Iqbal S and Lenz HJ: Determinants of prognosis and response to therapy in colorectal cancer. Curr Oncol Rep 3(2): 102-108, 2001.
10. Iqbal S, Stoehlmacher J and Lenz HJ: Tailored chemotherapy for colorectal cancer: a new approach to therapy. Cancer Invest 22(5): 762-773, 2004.
11. Seicean R, Funariu G and Seicean A: Molecular prognostic factors in rectal cancer. Rom J Gastroenterol 13(3): 223-231, 2004.
12. Ropponen K, Eskelinen M, Kosma VM, Lipponen P, Paakkinen P and Alhava E: Comparison of classic and quantitative prognostic factors in colorectal cancer. Anticancer Res 16(6B): 3875-3882, 1996.
13. Johnston PG: Of what value genomics in colorectal cancer? Opportunities and challenges. J Clin Oncol 1;22(9): 1538-1539, 2004.
14. Jalava P, Kronqvist P, Smrzova B, Juntti-Patinen L, Kuopio T and Collan Y: Nuclear volume and breast cancer prognosis. Anticancer Res 21(1B): 727-732, 2001.
15. Kronqvist P, Kuopio T, Jalava P and Collan Y: Morphometrical malignancy grading is a valuable prognostic factor in invasive ductal breast cancer. Br J Cancer 18; 87(11):1275-1280, 2002.
16. Eskelinen M, Lipponen P, Marin S, Haapasalo H, Makinen K, Ahtola H, Puittinen J, Nuutinen P and Alhava E: Prognostic factors in human pancreatic cancer, with special reference to quantitative histology. Scand J Gastroenterol 26(5): 483-90, 1991.
17. Nagashima T, Suzuki M and Nakajima N: Cytologic morphometric approach for the prediction of lymph node involvement in papillary thyroid cancer. Anal Quant Cytol Histol 19(1): 49-54, 1997.
18. Zhang YH, Kanamaru H, Oyama N, Miwa Y, Suzuki Y, Akino H, Noriki S and Okada K: Prognostic value of nuclear morphometry on needle biopsy from patients with prostate cancer: is volume-weighted mean nuclear volume superior to other morphometric parameters? Urology 55(3): 377-781, 2000.
19. Ikeguchi M, Sakatani T, Endo K, Makino M and Kaibara N: Computerized nuclear morphometry is a useful technique for evaluating the high metastatic potential of colorectal adenocarcinoma. Cancer 15:86(10): 1944-1951, 1999.
20. Mitmaker B, Begin LR and Gordon PH: Nuclear shape as a prognostic discriminant in colorectal carcinoma. Dis Colon Rectum 34(3): 249-259, 1991.
21. Heimann TM, Cohen RD, Szporn A and Gil J: Correlation of nuclear morphometry and DNA ploidy in rectal cancer. Dis Colon Rectum 34(6): 449-454, 1991.
22. Puente Dominguez JL: Prognostic value of optic morphometry in colorectal cancer. An R Acad Nac Med 117(3): 469-844, 2000.
23. Glimelius B, Ristamaki R, Kjaer M, Pfeiffer P, Skovsgaard T, Tveit KM, Linne T, Frodin JE, Boussard B, Oulid-Aissa D and Pyrhonen S: Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol 13(12): 1868-1873, 2002.
24. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 1;47(1): 207-214, 1981.
25. Baak JPA: Manual of Quantitative Pathology in Cancer Diagnosis and Prognosis. Berlin, Springer-Verlag, pp. 531-532, 1991.
26. Hytiroglou P, Harpaz N, Heller DS, Liu ZY, Deligdisch L and Gil J: Differential diagnosis of borderline and invasive serous cystadenocarcinomas of the ovary by computerized interactive morphometric analysis of nuclear features. Cancer 15:69(4): 988-992, 1992.
27. Mulder JW, Offerhaus GJ, de Feyter EP, Floyd JJ, Kern SE, Vogelstein B and Hamilton SR: The relationship of quantitative nuclear morphology to molecular genetic alterations in the adenoma-carcinoma sequence of the large bowel. Am J Pathol 141(4): 797-804, 1992.
28. Tosi P, Luzi P, Baak JP, Miracco C, Santopietro R, Vindigni C, Mattei FM, Acconcia A and Massai MR: Nuclear morphometry as an important prognostic factor in stage I renal cell carcinoma. Cancer 55(11): 2512-2518, 1986.
29. Pienta KJ and Coffey DS: Correlation of nuclear morphometry with progression of breast cancer. Cancer 1;68(9): 2012-2016, 1991.
30. Nafe R, Fritsch RS, Soudah B, Hamann A and Choritz H: Histomorphometry in paraffin sections of thyroid tumours. Pathol Res Pract 188(8): 1042-1048, 1992.
31. Ikeguchi M, Taniguchi T, Makino M and Kaibara N: Reduced E-cadherin expression and enlargement of cancer nuclei strongly correlate with hematogenic metastasis in colorectal adenocarcinoma. Scand J Gastroenterol 35(8): 839-846, 2000.
32. Ambros RA, Pawel BR, Meshcheryakov I, Kotrotsios J, Lambert WC and Trost RC: Nuclear morphometry as a prognostic indicator in colorectal carcinoma resected for cure. Anal Quant Cytol Histol 12(3): 172-176, 1990.
33. Hamilton PW, Wyatt JI, Quirke P, Watt PCH, Arthur K, Ward DC and Johnston D: Morphometry of gastric carcinoma: its association with patient survival, tumour stage, and DNA ploidy. J Pathol 168: 201-208, 1992.
34. Carson HJ, Buschmann RJ, Cintron J and Weisz-Carrington P: Prognostic histomorphometry in colorectal adenocarcinoma. Anal Quant Cytol Histol 17(2): 109-112, 1995.
35. Bendardaf R, Lamlum H, Ristamaki R, Algars A, Collan Y and Pyrhonen S: Response to chemotherapy (irinotecan plus 5-fluorouracil) in colorectal carcinoma can be predicted by tumour DNA content. Oncology 66(1): 46-52, 2004.
36. Yacoub SF, Shaeffer J, El-Mahdi AM, Paris L and Zhu A: Nuclear morphometry as a predictor of response to neoadjuvant chemotherapy plus radiotherapy in locally advanced cervical cancer. Gynecol Oncol 54(3): 327-332, 1994.
37. Iino H, Fukayama M, Maeda Y, Koike M, Mori T, Takahashi T, Kikuchi-Yanoshita R, Miyaki M, Mizuno S and Watanabe S: Molecular genetics for clinical management of colorectal carcinoma. 17p, 18q, and 22q loss of heterozygosity and decreased DCC expression are correlated with the metastatic potential. Cancer 73(5): 1324-1331, 1994.
38. Cohn KH, Ornstein DL, Wang F, LaPaix FD, Phipps K, Edelsberg C, Zuna R, Mott LA and Dunn JL: The significance of allelic deletions and aneuploidy in colorectal carcinoma. Results of a 5-year follow-up study. Cancer 79(2): 233-244, 1997.
39. Caldes T, Iniesta P, Vega FJ, de Juan C, Lopez JA, Diaz-Rubio E, Fernandez C, Cerdan J, Balibrea JL and Benito M: Comparative survival analysis of p53 gene mutations and protein accumulation in colorectal cancer. Oncology 55(3): 249-257, 1998.